source
- GSK to spend up to $1.3 billion on Hutchmed's dual-target cancer therapyGSK announced a deal to acquire the majority rights to Hutchmed's experimental therapy HMPL-A830. The agreement includes an upfront payment of $110 million and potential milestone and royalty payme…
- TScan Therapeutics slashes 75% of staff as it pivots to solid tumor programTScan Therapeutics announced on Sept. 2 that it is cutting roughly 75% of its workforce, about 104 employees, as part of a strategic reorganization. The move follows a November 2025 layoff that el…